Adnectin-targeted inhibitors: rationale and results

Area of Science:

• Biotechnology
• Protein Engineering
• Oncology

Background:

• Adnectins are engineered binding proteins based on the 10th type III domain of human fibronectin (10Fn3).
• The 10Fn3 scaffold offers structural stability and potential for therapeutic protein development.
• Adnectins can be engineered for specific molecular targets, including receptors involved in cancer progression.

Purpose of the Study:

• To review the therapeutic potential of adnectins, focusing on their development and preclinical and clinical applications.
• To evaluate the efficacy and safety of adnectin-based therapeutics, particularly CT-322, in cancer treatment.

Main Methods:

• Review of preclinical studies on adnectins, including CT-322 and El-Tandem.
• Analysis of clinical trial data for CT-322, including Phase I and Phase II studies.
• Assessment of adnectin binding affinities and inhibitory mechanisms.

Main Results:

• Preclinical studies indicated adnectins could reduce tumor growth, decrease microvessel density, and normalize tumor architecture.
• Phase I clinical trials of CT-322 (a vascular endothelial growth factor receptor-2 inhibitor) showed acceptable toxicity.
• Phase II trials of CT-322 in recurrent glioblastoma did not meet efficacy expectations.

Conclusions:

• Adnectins represent a promising class of therapeutics with potential in oncology.
• While early safety data for CT-322 were encouraging, its clinical efficacy in recurrent glioblastoma was limited.
• Further research into adnectin engineering and targeted applications is warranted.